Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
somatropin
|
| gptkbp:clinicalTrials |
ongoing
pediatric patients adult patients monitor for side effects not recommended for obesity recommended for pediatric use |
| gptkbp:contraindication |
active malignancy
hypersensitivity to somatropin acute critical illness |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
vial
1500 mcg/ml |
| gptkbp:drugInterdiction |
available online
protein synthesis glucocorticoids excreted in urine fat metabolism subcutaneous absorption anticonvulsants metabolized in liver estrogens growth promotion |
| gptkbp:firstAppearance |
2014-12-01
|
| gptkbp:formFactor |
injectable solution
|
| gptkbp:hasPopulation |
children
adults adolescents |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 1500
|
| gptkbp:is_monitored_by |
growth rate
blood glucose levels thyroid function |
| gptkbp:mandates |
gptkb:Turner_syndrome
gptkb:Prader-Willi_syndrome chronic kidney disease short stature |
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:packaging |
single-use vial
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchInterest |
long-term safety studies
ongoing efficacy studies comparative studies with other GH products |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
headache
nausea injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
diagnosis of growth hormone deficiency
|